First Patient Enrollment in Clinical Trial for Cellular Treatment of Peripheral Artery Disease

 

July 8, 2009

July 8, 2009 - Pluristem Therapeutics Inc. said yesterday its first patient enrolled in a phase I clinical trial that will evaluate the safety of the company’s allogeneic, placental-derived, adherent stromal cell product, termed PLX-PAD. The product is for use in patients afflicted with critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD). Up to 15 adults with the disease will be included in the trial, which is being conducted at the Franziskus-Krankenhaus Hospital and Charité - Universitätsmedizin Hospital in Berlin.

The Paul Ehrlich Institute recently approved the company to begin clinical trials with PLX-PAD.

PLX-PAD is a cellular therapeutic product derived from the placenta and is a ubiquitous source of adult stromal cells easily obtained without harm to the mother or baby.

For more information: www.pluristem.com

The content of this field is kept private and will not be shown publicly.
Type the characters you see in this picture. (verify using audio)
Type the characters you see in the picture above; if you can't read them, submit the form and a new image will be generated. Not case sensitive.